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Summary The expression of oestrogen regulated protein, P24, was investigated in 69 breast cancers. At initial
evaluation P24 protein was detected significantly more frequently and was present in significantly higher
concentration in oestrogen receptor positive than in receptor negative tumours. There was, however, no
correlation between P24 staining and progesterone receptor, tumour ploidy or proliferative index. Nineteen
patients received a short course of treatment with diethylstilboestrol. Following treatment with oestrogen, P24
staining became positive in 7/13 tumours previously negative for P24, including six tumours which were
oestrogen receptor negative. Oestrogen administration also caused an increase of the proliferation index in
12/19 tumours, including 5/7 that were oestrogen receptor positive and 7/12 that were oestrogen receptor
negative. In some instances oestrogenic stimulation of proliferation occurred together with increased P24
expression; in other instances proliferation index increased without induction of P24 synthesis. The in vivo
effects of oestrogen in clinical breast cancer thus appear to show dissociation between enhancement of protein
synthesis and cellular proliferation.
Oestrogenic effects in hormone responsive tissues such as the
breast include induction of protein synthesis as well as in-
creased proliferation. In addition, oestrogens appear to play
an important role in the development, maintenance and
growth of breast tumours. The currently held hypothesis is
that these oestrogenic effects are mediated through the
interaction of hormone and specific nuclear oestrogen recep-
tor (ER). While the presence of specific oestrogen and pro-
gesterone (PR) receptors appears to be an important deter-
minant of response to hormone treatment (Whitliff, 1983;
Cant et al., 1985; Vollenweider-Zerargul et al., 1986; Wil-
liams et al., 1987), in breast cancer not all receptor positive
tumours are amenable to hormonal manipulation. However,
absence of receptor is associated with a low probability of
response to hormone therapy.
Apart from the utility of receptors as predictors for res-
ponse to hormonal treatment an important pathopysiological
consideration in breast cancer is the influence of endogenous
hormones on tumour genesis, promotion and growth. These
effects are also thought to be mediated through the receptor
mechanism. Steroid receptors are, however, demonstrated
only in a proportion of breast cancers (Allegra et al., 1979;
Mohla et al., 1982; McGuire et al., 1984). Whether receptor
negative tumours are independent of hormonal influence
requires elucidation.
Recently two oestrogen regulated proteins, P24 (Edwards
et al., 1981; Ciocca et al., 1982, 1984; Adams et al., 1983;
Adams & McGuire, 1985) and P52 (Veith et al., 1983; Garcia
et al., 1984, 1985; Rochefort et al., 1987) have been de-
scribed. The study of such oestrogen regulated proteins may
give insight into the mechanisms of hormone action in breast
cancer.
In the MCF 7 breast cancer cell line P24 expression
appears to be constitutive but with only low levels of P24
being produced in the absence of exogenous oestrogenic
stimulation. However, in this experimental model oestrogen
exposure results in both new mRNA expression as well as
increased P24 protein synthesis, suggesting that the gene is
oestrogen inducible. Whether such effects are seen in vivo is
at present unknown. We have thus chosen to study P24
expression in hormonal regulation of a model of the protein
synthesis in human breast cancer.
Materials and methods
Monoclonal IgG antibody to P24 was a generous gift from
Dr W. McGuire (University ofTexas Health Science Centre).
Avidin-biotin reagent (Vectastain ABC Kit) was obtained
from Vector (Vector Laboratories, Burlinghame, CA, USA).
Non-immune mouse IgG and DAB were purchased from
Sigma (Sigma Chemical Co., St Louis, MO, USA).
Specimens were obtained by either surgical biopsy or nee-
dle biopsy (Truecut), under local anaesthetic, of accessable
tumours. Most were metastatic tumours at cutaneous sites or
primary breast tumours. The specimens were transported on
ice and either processed immediately or stored at - 135'C for
later use. All specimens were examined for the presence of
tumour by routine haematoxylin and eosin stained sections.
Sections immediately adjacent to those histologically involved
with tumour were used for immunocytochemical determina-
tions.
P24 immunocytochemistry
Frozen sections were placed on HCI-ethanol cleaned slides.
Specimens were fixed by immersion in 3.7% formalin for 10
minutes followed by ice cold methanol for 4 minutes and
then in ice cold acetone for 1-2 minutes. Slides were rinsed
with cold phosphate-buffered saline (PBS) and immersed in
H202 -methanol (to block endogenous peroxidase) and then
rinsed again. Thereafter slides were incubated for 3 hours
with monoclonal anti-P24 antibody (5pg ml- ') (Ciocca et al.,
1983a) at 20C. Biotinylated secondary antibody was applied
at a 1:400 dilution. The reaction was developed with DAB.
Slides were counterstained with Meyer's Haematoxylin,
serially dehydrated with graded alcohols and xylene and then
mounted with coverslips. All assays were performed with
negative controls, substituting non-immune mouse IgG for
primary antibody, and with a positive control utilising MCF-
7 cells grown under optimal conditions for hormone receptor
and P24 expression. Slides were examined at
400 x magnification. Assessment of immunocytochemical
staining used for the following scoring system: 0, negative; 1,
weak staining, present in 1-10% of cells; 2, moderate stain-
ing, present in 11-50% ofcells; 3, intense staining, present in
51-90% of cells; 4, intense staining, present in 91-100% of
cells.
Immunocytochemical stainingfor ER and PR
Immunocytochemical staining for ER was performed using
the Abbot ER-ICA kit (King et al., 1985; Thorpe, 1987)
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(Abbot Laboratories) according to the manufacturers' ins-
tructions. Immunocytochemical staining for PR was per-
formed according to previously described methods (Logeat et
al., 1983; Perrot-Applanat, 1985, 1987) using an monoclonal
antibody to rabbit PR which cross-reacts with human PR
and has been shown to be highly specific for the receptor.
Assessment of immunocytochemical staining for ER and PR
used the same scoring system as for P24.
All immunocytochemical assays were performed analysing
a miniumum of 10 fields and counting at least 100 cells per
field to give an overall score. Only tumour cells were counted
for the estimation of degree of positivity. When serial biop-
sies were performed they were performed from the same
tumour area.
Flow cytometric analysis oftumour cellploidy andproliferative
index
Flow cytometry was performed using a Coulter Epics
cytometer after enzymatic digestion ofminced fresh or frozen
tissue fragments and staining with propidium iodide. DNA
distribution was compared to a standard of human lym-
phocyte nuclei as well as normal breast tissue freshly
prepared in similar fashion to the tissue fragments. Aneu-
ploid tumours were defined as those with DNA indices lower
or higher than 1.0- 1.1 Proliferative index (PI) was calculated
by summation of cells in S and G2M. All estimations were
performed in triplicate. Only studies where the coefficient of
variation was <5% were considered analysable. Significant
stimulation of PI following oestrogen exposure was defined
as a rise in PI >10% from the pretreatment value.
Patients
A total of 74 patients were studied. Of the 74 patients, 20
were caucasian and 54 were black. All patients had locally
advanced primary disease or metastatic disease with tumours
accessable for biopsy. The initial evaluations were performed
before any hormone therapy or chemotherapy. Sixty-nine
patients had evaluable results for all parameters i.e. ploidy,
receptor status and P24 staining before therapy.
Apart from the pretreatment investigations 24 patients
were investigated serially during the course of a randomised
ongoing study of the effects of hormone priming before
chemotherapy. Patients were eligible for this study whether
ER + or ER- and were randomly allocated to receive either
hormone priming followed by chemotherapy or
chemotherapy alone. Nineteen of the 24 patients had been
randomised to the hormone priming arm and were evaluated
following a short exposure to oestrogen (given as diethylstil-
boestrol 5 mgday-' x 5 days). Biopsies were performed
immediately before and immediately after hormone adminis-
tration. Five patients were evaluated before and after
chemotherapy without any prior hormonal priming.
The study was approved by the Ethics Committee of the
University of the Witwatersrand and was carried out in
accordance with the principles of the Declaration of Helsinki.
Results
The results using the histocytochemical assays were highly
reproducible. Inter and intra-observer variation was minimal
with a correlation coefficient of >0.9 for single biopsy speci-
mens. When multiple simultaneous biopsies were carried out
on the same patient (19 patients had multiple simultaneous
biopsies) the overall scores, taking into account 10 fields
from each biopsy sample, were also consistent with a correla-
tion coefficient >0.9.
Approximately 50% of samples obtained before therapy
showed positive staining for P24 (Table I). There were no
significant differences in the proportion showing P24 staining
when black or white patients, those with aneuploid or diploid
tumours, or PR positive and PR negative tumours were
compared. P24 staining was, however, found to be
Table I Pretreatment immunocytochemical staining for P24 protein
Patient P24 staining intensity Total
characteristics 0 1 2 3 4 positive (%)
Premenopausal 10 7 1 3 0 11/12 (52)
Post-menopausal 25 8 9 5 1 23/48 (48)
Black 27 12 5 6 1 24/51 (47)
White 8 3 5 2 0 10/18 (55)
Diploid 19 7 4 4 1 16/35 (46)
Aneuploid 16 8 6 4 0 18/34 (53)
ER+ PR+ 3 2 1 2 1 6/9 (66)
ER + PR- 5 4 2 4 0 10/15 (66)
ER-PR+ I 1 0 0 0 1/2 (50)
ER- PR- 26 8 7 2 0 17/43 (39)
Grades I and 2 8 9 5 2 1 17/25 (68)
Grades 3 and 4 27 10 5 2 0 17/44 (41)
Locoregional
(stage II)
disease 5 2 1 3 1 7/12 (58)
Metastatic
disease 30 13 9 5 0 27/57 (47)
significantly, more frequent in ER positive tumours (16/24;
67%) when compared to ER negative tumours (18/45; 40%)
(X2 = 4.50, P<0.05). Furthermore, the intensity of P24 stain-
ing correlated significantly with ER content (Spearman cor-
relation 0.434, P = 0.001).
Histological grade also correlated significantly with P24
expression with 17/25 grade 1 and 2 tumours showing P24
positivity, while only 11/44 grade 3 tumours were P24
positive (2= 5.5, P<0.05).
Results following hormone treatment (DES 5 mg day-' x 5
days) are shown in Tables II and III. Of the six tumours that
were P24 positive before oestrogen exposure four remained
P24 positive and two became P24 negative following treat-
ment with DES (Table II). Of the 13 tumours that were P24
negative before hormone treatment seven became positive for
P24 after oestrogen administration. P24 induction was noted
in 6/9 ER negative as well as 1/4 in ER positive tumours.
Oestrogenic stimulation of cell growth (as defined by an
increase of proliferative index >10% from base line values)
was seen in 12/19 patients given a short course of diethylstil-
boestrol. The 12 tumours which showed an increase of pro-
liferation index after oestrogen treatment included 5/7 that
were ER positive and 7/12 that were ER negative before
hormone administration.
The relationships between P24 expression and alteration of
proliferation index were also complex. Proliferation index
increased in 3/6 tumours that were initially P24 positive and
in 9/13 that were initially P24 negative. Among the tumours
that were initially P24 positive, two showed increased pro-
liferation together with loss of P24 expression while one
remained p24 positive within increased proliferation follow-
ing oestrogen. On the other hand, among the nine tumours
that were initially P24 negative and which showed an in-
crease in proliferation index, six had P24 induction with
increased proliferation while three showed an increase in
proliferation with P24 remaining negative. In two instances
there was a significant decrease of proliferation index follow-
ing 5 days of diethylstilboestrol therapy. Both were tumours
that were ER + and PR- and in both instances PR was
induced by oestrogen exposure together with the decrease of
proliferation index. In addition P24 expression was also
induced in one of these tumours.
The effects of oestrogen administration on hormone recep-
tor expression are shown in Table III. Following diethylstil-
boestrol ER was no longer detectable in 6/7 previously ER
positive tumours while in the one tumour that remained ER
positive there was a significant decrease in the ER content.
At the same time PR either increased in concentration or
became positive. In those tumours that were initially ER
negative there was, however, no change of either ER or PR
status following diethylstilboestrol.
No significant changes in P24, or hormone receptor expres-
sion were observed in tumours from those patients who888 L. SEYMOUR et al.
Table II Effect of oestrogen (diethylstylboestrol) and ofchemotherapy on in vivo P24
expression and cell proliferation
Pretreatment After oestrogen administration
P24 expression Proliferative indexa
Hormone Remained Became
receptors Positive positive negative Up Down NC
ER+ PR+ 1 1 0 0 0 1
ER + PR- 2 1 1 2 0 0
ER- PR- 3 2 1 1 1 1
Total 6 4 2 3 1 2
Remained Became
Negative negative positive UP Down NC
ER+ PR+ 2 1 1 2 0 0
ER+ PR- 2 2 0 1 0 1
ER-PR + I 1 0 1 0 0
ER-PR- 8 2 6 5 1 2
Total 13 6 7 9 1 3
Pretreatment After chemotherapy
P24 expression Proliferative index
Hormone Remained Became
receptors Positive positive negative Up Down NC
ER+ PR+ 1 1 0 0 0 1
ER+ PR- 1 1 0 0 1 0
ER-PR- I 1 0 0 0 1
Total 3 3 0 0 1 2
Remained Became
Negative negative positive UP Down NC
ER-PR- 2 2 0 0 1 1
aUp, increase in proliferative index >10%; down, decrease in proliferative index
>210%; no change in proliferative index.
Table III Effects on oestrogen (diethylstilboestrol) and of chemotherapy on in vivo
hormone receptor expression
Hormone receptors ER + PR + ER + PR- ER- PR+ ER- PR-
Pretreatment After oestrogen administration
ER+ PR+ 3 1 0 2 0
ER+ PR- 4 0 0 3 1
ER-PR + 1 0 0 1 0
ER-PR- 11 0 0 0 11
Total 19 1 1 6 12
After chemotherapy
ER+ PR+ I 1 0 0 0
ER+ PR- I 0 1 0 0
ER-PR- 3 0 0 0 3
Total 5 1 1 0 3
received chemotherapy only. Furthermore no instances of
increase in proliferation index were observed following
chemotherapy.
Discussion
The 24,000 Da protein, P24, was first detected in MCF-7
cells and appears from protein studies to be an oestrogen
regulated (Edwards et al., 1981) secretory protein (Ciocca et
al., 1982; Adams et al., 1983). Following these initial inves-
tigations P24 has also been found in other oestrogen receptor
positive cell lines (Ciocca et al., 1983b) as well as in highly
oestrogen responsive target tissues such as human decidua
(Ciocca et al., 1983c) and in certain cells of the female genital
tract (Ciocca et al., 1983b). Recent DNA sequencing studies
have shown that the P24 protein is identical with a human
heat shock protein, designated as hsp27, which was first
detected in HeLa cells (Fuqua et al., 1990). P24 is generally
not found in normal or hyperplastic breast tissue.
While the synthesis of P24 appears to be constitutive in
MCF-7 cells, both mRNA expression and synthesis of the
protein are selectively increased in MCF-7 by oestrogenic
stimulation. Recent investigations have shown that heat
shock can also induce P24 synthesis in MCF-7 cells (Hickey
et al., 1986). While the function of P24/hsp27 is unknown,
the selective tissue expression and its apparent control by
oestrogen suggested that P24 might be a useful marker for
the study of oestrogen action in breast cancer, both as an
indicator of endogenous hormonal action and possible as a
predictor of hormone responsiveness.
The correlation between initial oestrogen receptor status
and P24 expression and between histological grade and P24
expression suggest that the expression of these biological
tumour markers is in some way linked. In this regard the
comparison between black and white patients is of some
interest. Previous studies have suggested a lower frequency of
receptor positive tumours among black women than among
caucasian women (Savage et al., 1980; Mohla et al., 1982;
Pegoraro et al., 1986). A previous study from this institution
(Dansey et al., 1988) demonstrated, however, that black
patients with breast cancer have a significantly younger age
distribution, thus raising the possibility of ER masking by
endogenous oestrogens when ER estimations are performed
by ligand binding methods. The study of P24 might thus
offer a means of establishing the presence of endogenous
hormone action in apparently ER- tumours. Consistent
with this hypothesis the present study showed no significant
differences between black and white subjects in regard to P24
expression. It should be pointed out, however, that in the
present study, where immunocytochemical methods were
used for ER and PR estimation, there were also no
significant differences in ER or PR status between the two
racial groups.P24 IN BREAST CANCER 889
While the correlation between baseline P24 and ER status
was significant, P24 expression was by no means confined to
ER positive tumours. The presence of P24 in ER- tumours
could be due to constitutive production of the protein by
tumour cells or the induction of synthesis by oestrogen in the
absence of detectable ER. In this regard the results following
exposure to oestrogen have to be taken into account. Follow-
ing oestrogen administration P24 induction was noted in 7/13
tumours previously negative for P24. There was, however, no
correlation, in vivo, between ER content and oestrogen
induced synthesis of P24.
The influence of diethylstiboesterol on cell proliferation
appeared also to be independent of ER with both ER + and
ER- tumours, showing an increase of proliferation as
assessed by flow cytometric analysis. The validity of the flow
cytometric measurements was confirmed by clinical observa-
tions which showed a highly significant correlation between
clinical tumour flare and an increase in the proliferative index
(x2 = 17.4, P<O.OOO1). Tumour flares following oestrogen
administration occurred in ER- as well as in ER +
patients.
The changes observed in hormone receptor expression fol-
lowing oestrogen exposure, on the other hand, did follow a
pattern predicted by in vitro models, i.e. reduction of ER
content and induction of PR expression (Nardulli et al.,
1988), which occurred only in ER positive tumours.
That these results were due to the administered oestrogen
and not to sampling error is shown by the findings in those
patients receiving chemotherapy only. There were no changes
in either P24 or hormone receptor expression following
chemotherapy without hormone priming. Furthermore, there
was no instance of an increase in proliferation index follow-
ing chemotherapy alone.
The patterns of response following in vivo oestrogen
exposure were thus variable and included: (a) induction of
new protein synthesis; (b) induction of new protein synthesis
together with stimulation of proliferation; (c) stimulation of
proliferation occurring without induction of new protein syn-
thesis. While some of these effects, e.g. induction of PR
synthesis, appear to be dependent on the presence of specific
oestrogen receptor, increased proliferation of P24 synthesis
can be induced by oestrogens in the apparent absence of
specific ER. In this regard it should be pointed out that since
receptor status was determined by demonstration of ER pro-
tein by means of immunological rather than ligand binding
methods these results are unlikely to be due to receptor
masking by high endogenous steroid levels (Thorpe, 1987).
While it remains possible that oestrogenic effects were due
to the presence of receptor at concentrations not detectable
by current immunological techniques the possibility should
be considered that oestrogens can exert significant effects in
clinical breast cancer by mechanisms other than binding to
specific ER.
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